Table 2 Prevalence of sequelae or persistent symptoms (SPS) 12 months after discharge
SPS | Exposed cohort (hospitalised due to COVID-19) (n = 453) | Non-exposed cohort (hospitalised due to other causes) (n = 453) | P-value1 |
|---|---|---|---|
n (%) | n (%) | ||
Any SPS | 163 (36.1) | 160 (35.3) | 0.797 |
General/systemic SPS | 68 (15.0) | 80 (17.7) | 0.281 |
Fatigue | 37 (8.2) | 56 (12.4) | 0.038 |
Muscle weakness | 14 (3.1) | 8 (1.8) | 0.195 |
Muscle or joint pain | 42 (9.3) | 48 (10.6) | 0.505 |
Respiratory SPS | 87 (19.2) | 72 (15.9) | 0.190 |
Dyspnoea | 70 (15.5) | 56 (12.4) | 0.179 |
Chest pain | 5 (1.1) | 8 (1.8) | 0.578 |
Pharyngeal symptoms | 16 (3.5) | 2 (0.4) | <0.001 |
Neurological SPS | 44 (9.7) | 28 (6.2) | 0.049 |
Headache | 13 (2.9) | 12 (2.6) | 0.839 |
Sensitivity disorders | 9 (2.0) | 8 (1.8) | 0.807 |
Movement disorders | 5 (1.1) | 1 (0.2) | 0.062 |
Confusion, memory loss | 16 (3.5) | 8 (1.8) | 0.043 |
Mental health SPS | 48 (10.6) | 46 (10.2) | 0.828 |
Depressive symptoms | 22 (4.9) | 20 (4.4) | 0.752 |
Anxiety symptoms | 33 (7.3) | 19 (4.2) | 0.046 |
Sleep disturbances | 17 (3.8) | 14 (3.1) | 0.584 |
Haematological SPS | 7 (1.5) | 7 (1.5) | 1.000 |
Thrombotic events | 5 (1.1) | 0 (0.0) | 0.025 |
Dermatological SPS | 9 (2.0) | 24 (5.3) | 0.008 |
Nephrological SPS | 5 (1.1) | 2 (0.4) | 0.162 |
Urological SPS | 6 (1.3) | 16 (3.5) | 0.031 |
Otorhinolaryngological SPS | 6 (1.3) | 8 (1.8) | 0.590 |
Ophthalmological SPS | 5 (1.1) | 16 (3.5) | 0.015 |
Digestive SPS | 9 (2.0) | 32 (7.1) | <0.001 |
Diarrhoea | 4 (0.9) | 16 (3.5) | 0.007 |
Constipation | 3 (0.7) | 8 (1.8) | 0.129 |
Abdominal pain | 4 (0.9) | 16 (3.5) | 0.007 |
Infection | 7 (1.5) | 6 (1.3) | 0.898 |